Localizing Pathologic Response After Neoadjuvant Immunotherapy For Stage Iii Melanoma

Localizing Pathologic Response After Neoadjuvant Immunotherapy for Stage III Melanoma

The personalization of neoadjuvant immunotherapy in stage III melanoma

Pathologic Response After Neoadjuvant Immunotherapy: Facilitating Progress in Early-Stage Cancers

PeerView Oncology

NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

Impact of emotional distress on pathologic response in high-risk stage III melanoma

Response-Driven Surgery and Adjuvant Therapy After Neoadjuvant Immunotherapy for Stage III Melanoma

OpACIN-neo & PRADO 3-year results in stage III melanoma: personalized neoadjuvant IO benefits

Neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage III melanoma

PRADO: personalized response-driven therapy in resectable stage III melanoma

Adjuvant and Neoadjuvant Dilemmas

SWOG S1801: pathologic response in neoadjuvant-adjuvant vs. adjuvant pembro for resectable melanoma

PRADO: personalized response-driven surgery and adjuvant therapy in stage III melanoma

Neoadjuvant therapy in bulky Stage III melanoma

Advances in utilizing neoadjuvant immunotherapy in melanoma

Expert Opinion: Use of Adjuvant and Neoadjuvant Approaches in Patients With Stage III Melanoma

Dr. Eggermont on Responses to Adjuvant Pembrolizumab in Stage III Melanoma Subtypes

Omitting total lymph node dissection and adjuvant therapy in melanoma

Expert report on neoadjuvant immune checkpoint inhibitors for Melanoma

European Society for Medical Oncology (ESMO)

Neoadjuvant Therapy and Adjuvant Therapy (pre and post-surgery) for Melanoma

Adjuvant and Neoadjuvant Therapy for Melanoma Weber 2021